Communiqués Gan & Lee Pharmaceuticals.

Actions

603087

CNE100003ZH1

Produits pharmaceutiques

Cours en clôture Shanghai S.E. 24/09/2026			Varia. 5j.	Varia. 1 janv.
73,44 ^CNY	-1,50%		+6,51%	+7,89%

21/09	Gan & Lee Pharmaceuticals obtient l'approbation pour l'essai clinique du GLR1075 en Chine ; l'action grimpe de 3%	MT
09/09	Gan&Lee Pharmaceuticals Co., Ltd. administre la première dose au premier participant de l'étude de phase 1 chez l'homme pour les comprimés GZC8072	CI

Communiqués

09/09	First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA	AQ
12/06	Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.	AQ
09/04	Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide	AQ
31/03	Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2	AQ
27/11	Once-Monthly GLP-1 RA \| Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management	AQ
21/06/25	Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions	AQ
10/03/25	Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity	AQ
18/12/24	Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)	AQ
12/11/24	Malaysian Deputy Prime Minister Attends Groundbreaking Ceremony of Gan & Lee Pharmaceuticals Partner Factory	AQ
12/11/24	Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks	AQ
11/11/24	ObesityWeek®️ 2024 \| Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults	AQ
15/10/24	Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies	AQ
14/09/24	Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)	AQ
23/07/24	Gan & Lee Pharmaceuticals Bi-weekly twice a month GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial	AQ
22/07/24	Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial	AQ
22/06/24	Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions	AQ
18/06/24	Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions	AQ
10/03/22	Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18	AQ
14/10/21	Gan & Lee Pharmaceuticals : Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)	AQ
02/07/21	Gan & Lee Pharmaceuticals : New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association's 81st Scientific Sessions	AQ